BioNexus Gene Lab Corp.
BGLC
$5.38
-$0.04-0.74%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -33.00% | 20.49% | 39.20% | 69.57% | -291.86% |
| Total Depreciation and Amortization | 44.71% | 44.52% | 41.20% | 33.37% | 18.44% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -237.82% | -232.56% | -256.60% | -216.32% | -268.47% |
| Change in Net Operating Assets | 107.28% | -232.98% | -2.04% | -136.74% | -119.45% |
| Cash from Operations | -29.27% | -73.61% | -22.87% | -424.34% | -470.57% |
| Capital Expenditure | -47.41% | -25.06% | -51.87% | -35.23% | -350.57% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 132.08% | 135.49% | 136.78% | -420.17% | -33,821.74% |
| Cash from Investing | 115.53% | 120.10% | 121.07% | -268.08% | -4,230.23% |
| Total Debt Issued | -192.06% | -157.36% | -70.45% | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -97.75% | -97.75% | -97.75% | -91.10% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -2.38% | 155.56% | -- | 148.35% | 151.22% |
| Cash from Financing | -100.84% | -98.07% | -97.62% | -90.69% | 79,141.46% |
| Foreign Exchange rate Adjustments | 347.10% | 150.29% | 115.52% | 765.19% | 6.48% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -211.87% | -196.91% | -169.66% | -173.89% | 426.78% |